Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 71

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 71
---
 is timely furnished to the IRS.

Each U.S. Holder is urged to consult with its tax advisor concerning the United States federal income tax consequences of purchasing, holding, and disposing of our common shares if we are or become classified as a PFIC, including the procedure for, and the possibility and consequences of, making a purging or mark-to-market election. We cannot provide any assurances that the IRS will agree with our annual determinations of our PFIC status.

<div align='center'>S-21

EXPENSES OF THIS OFFERING</div>

We estimate that our expenses in connection with this offering, other than underwriting discounts and commissions, will be as follows:

| SEC registration fee                           |     | $ | 15,310 |
| Printing and engraving expenses                |     |   |  5,000 |
| Legal fees and expenses                        |     |   | 40,000 |
| Transfer agent and registrar fees and expenses |     |   |  5,000 |
| Accounting fees and expenses                   |     |   | 15,000 |
| Miscellaneous costs                            |     |   |  4,690 |
| Total                                          |     | $ | 85,000 |

<div align='center'>PLAN OF DISTRIBUTION</div>

We have previously entered into a sales agreement with Jefferies, under which we may offer and sell our common shares from time to time through Jefferies acting as agent. Pursuant to this prospectus, we may offer and sell our common shares having an aggregate offering price of up to $100 million. Sales of our common shares, if any, under this prospectus supplement will be made by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act.

Each time we wish to issue and sell common shares under the Sales Agreement, we will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the Sales Agreement to sell our common shares are subject to a number of